Full Breakdown
FBI Investigates Circumstances Surrounding Jim Irsay's Death
1/22/2026, 11:37:53 PM
Overview of the Investigation
The FBI has initiated an investigation into the death of former Indianapolis Colts owner Jim Irsay, who passed away on May 21, 2025, at the age of 65. The inquiry focuses on the circumstances surrounding his death, particularly his substance use and his relationship with Dr. Harry Haroutunian, a California-based addiction specialist who prescribed Irsay painkillers and ketamine in the months leading up to his death. A federal grand jury subpoena has been issued for records related to Irsay's death, his substance use, and his interactions with Haroutunian.
Key Details Surrounding Irsay's Death
Irsay's death certificate, signed by Dr. Haroutunian, attributed the cause of death to cardiac arrest triggered by acute pneumonia, with contributing factors including two heart conditions. Notably, no autopsy was performed, and police in Beverly Hills did not suspect an overdose as a cause of death. Reports indicate that Haroutunian had prescribed over 200 opioid pills to Irsay, which allegedly led to two overdoses in December 2023. Irsay had publicly claimed to be clean from opioids, but investigations suggest that his treatment regimen may have contributed to his relapse.
Background on Jim Irsay
Jim Irsay became the owner of the Indianapolis Colts in 1997 and was known for his open discussions about his struggles with addiction. He was a prominent advocate for mental health awareness through his nonprofit initiative, Kicking the Stigma, launched after a DUI arrest in 2014. Under his leadership, the Colts won one Super Bowl and were recognized as one of the NFL's top teams.
Official Statements & Responses
Colts Chief Legal Officer Dan Emerson confirmed that the team is aware of the FBI investigation but stated that they have not been contacted or served with subpoenas. Emerson noted, “I do understand that there have been some subpoenas provided, but not to me, the Colts, or any of our current employees.” Dr. Haroutunian has not publicly commented on the investigation.
Criticism & Opposition
Concerns have been raised regarding the treatment Irsay received from Haroutunian, particularly the large quantities of opioids prescribed. Critics argue that the medical oversight in Irsay's case may have been inadequate, contributing to his health decline. The investigation aims to clarify the extent of Haroutunian's role in Irsay's substance use and the appropriateness of his treatment methods.
Conflicting Reports & Gaps
While the FBI investigation is ongoing, there are discrepancies regarding the nature of Irsay's death. Some reports suggest that there were no signs of overdose at the scene, while others highlight the significant amount of opioids prescribed to him. The lack of an autopsy has also raised questions about the thoroughness of the initial investigation into his death.
What's Next
As the FBI continues its investigation, further developments are expected, including potential interviews with individuals close to Irsay during his final years. The outcomes of this investigation may have implications for medical practices surrounding addiction treatment and oversight in similar cases.
